Key statistics
On Thursday, SAGE Therapeutics Inc (SAGE:NMQ) closed at 4.85, 4.98% above its 52-week low of 4.62, set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.02 |
---|---|
High | 5.19 |
Low | 4.80 |
Bid | 4.75 |
Offer | 5.26 |
Previous close | 4.91 |
Average volume | 895.87k |
---|---|
Shares outstanding | 61.17m |
Free float | 53.88m |
P/E (TTM) | -- |
Market cap | 296.69m USD |
EPS (TTM) | -5.58 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
- Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
- Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
- Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
- Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
- Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
More ▼